[go: up one dir, main page]

WO2004080375A3 - Vaccin - Google Patents

Vaccin Download PDF

Info

Publication number
WO2004080375A3
WO2004080375A3 PCT/EP2004/002643 EP2004002643W WO2004080375A3 WO 2004080375 A3 WO2004080375 A3 WO 2004080375A3 EP 2004002643 W EP2004002643 W EP 2004002643W WO 2004080375 A3 WO2004080375 A3 WO 2004080375A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunogens
apociii
atherosclerosis
present
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/002643
Other languages
English (en)
Other versions
WO2004080375A2 (fr
Inventor
Rene Meykens
Pascal Mettens
Philippe Monteyne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of WO2004080375A2 publication Critical patent/WO2004080375A2/fr
Publication of WO2004080375A3 publication Critical patent/WO2004080375A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0012—Lipids; Lipoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention se rapporte à de nouvelles thérapies vaccinales et à des traitements prophylactiques de maladies artériosclérotiques. On prévoit des immunogènes contenant des fragments ou dérivés spécifiques de l'Apolipoproteine C-III (ApoCIII). Les vaccins de cette invention, renfermant les immunogènes, sont puissants en terme de prévention, ou de réduction, de la formation de plaque artériosclérotique sur des périodes prolongées, ce qui a pour effet de réduire le risque que l'artériosclérose n'entraîne des maladies coronaires ou cérébrovasculaires. Font également l'objet de cette invention des méthodes de traitement ou de prévention de l'artériosclérose par vaccination active, ou vaccination passive, au moyen d'administration à un patient d'un anticorps apte à se lier à des fragments spécifiques de ApoCIII. Des anticorps monoclonaux spécifiques et leur utilisation dans la thérapie de l'artériosclérose font également l'objet de cette invention. L'invention concerne par ailleurs l'utilisation des immunogènes de cette invention dans le domaine médical, et leurs procédés de production. Les fragments d'ApoCIII formant la base des immunogènes de cette invention ainsi que les cibles d'immunothérapie passive se trouvent au sein des zones entre les nombres 45-76 d'acides aminés et, plus particulièrement, entre 12-35 de la forme adulte de l'ApoCIII humaine.
PCT/EP2004/002643 2003-03-13 2004-03-11 Vaccin Ceased WO2004080375A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0305794.0 2003-03-13
GBGB0305794.0A GB0305794D0 (en) 2003-03-13 2003-03-13 Vaccine

Publications (2)

Publication Number Publication Date
WO2004080375A2 WO2004080375A2 (fr) 2004-09-23
WO2004080375A3 true WO2004080375A3 (fr) 2005-01-13

Family

ID=9954733

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/002643 Ceased WO2004080375A2 (fr) 2003-03-13 2004-03-11 Vaccin

Country Status (2)

Country Link
GB (1) GB0305794D0 (fr)
WO (1) WO2004080375A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23736A1 (es) 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
EP3481864A1 (fr) * 2016-07-08 2019-05-15 Staten Biotechnology B.V. Anticorps anti-apoc3 et leurs méthodes d'utilisation
CA3059133A1 (fr) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anticorps anti-apoc3 et leurs methodes d'utilisation
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
MA50516A (fr) 2017-10-31 2020-09-09 Staten Biotechnology B V Anticorps anti-apoc3 et leurs procédés d'utilisation
US11690901B2 (en) * 2020-03-03 2023-07-04 The United States Of America, As Represented By The Secretary Of Agriculture Southern cattle tick vaccine product
JP2024500035A (ja) 2020-12-23 2024-01-04 アルゴノート アールエヌエー リミテッド 心血管疾患の治療
US20250283076A1 (en) 2021-09-14 2025-09-11 Argonaute RNA Limited Treatment of cardiovascular disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0378881A1 (fr) * 1989-01-17 1990-07-25 ENIRICERCHE S.p.A. Peptides synthétiques et leur utilisation comme support universel pour la préparation de conjugués immunogènes convenant au développement de vaccins synthétiques
WO2001064008A2 (fr) * 2000-03-03 2001-09-07 Smithkline Beecham Biologicals S.A. Vaccins
WO2003020765A2 (fr) * 2001-08-31 2003-03-13 Glaxosmithkline Biologicals S.A. Vaccins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0378881A1 (fr) * 1989-01-17 1990-07-25 ENIRICERCHE S.p.A. Peptides synthétiques et leur utilisation comme support universel pour la préparation de conjugués immunogènes convenant au développement de vaccins synthétiques
WO2001064008A2 (fr) * 2000-03-03 2001-09-07 Smithkline Beecham Biologicals S.A. Vaccins
WO2003020765A2 (fr) * 2001-08-31 2003-03-13 Glaxosmithkline Biologicals S.A. Vaccins

Also Published As

Publication number Publication date
GB0305794D0 (en) 2003-04-16
WO2004080375A2 (fr) 2004-09-23

Similar Documents

Publication Publication Date Title
WO2003020765A3 (fr) Vaccins
WO2001064008A3 (fr) Vaccins
WO2003090686A3 (fr) Utilisation de proteines de choc thermique pour ameliorer l'avantage therapeutique d'une modalite de traitement non vaccinal
WO2002034205A3 (fr) Utilisation des proteines du stress pour stimuler la reponse immunitaire
WO2002056905A3 (fr) Jeu ordonne d'echantillons d'antigenes moleculaires
JP2004501101A5 (fr)
WO2005063201A3 (fr) Liposomes et compositions liposomales pour la vaccination et l'administration de medicaments
BRPI0610093A2 (pt) composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente
BRPI0010612B8 (pt) vacinas
WO2010067286A3 (fr) Vaccin peptidique ige ch3
JP2006506441A5 (fr)
WO2010016912A3 (fr) Compositions immunothérapeutiques pour le traitement de la maladie d'alzheimer
WO2001053457A3 (fr) Vaccins contre certains troubles neurodegeneratifs
WO2004080375A3 (fr) Vaccin
WO2003059385A3 (fr) Vaccin contre le vih et procede d'utilisation
WO2004081045A3 (fr) Vaccin
JP2007513992A5 (fr)
WO2003090687A3 (fr) Utilisation de proteines de choc thermique pour renforcer la reponse immunitaire
AU2003263712A1 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
WO2002060435A8 (fr) Cryptotanshinone permettant de prevenir et d'attenuer la maladie d'alzheimer
Pfützner et al. AIT: new avenues in allergen immunotherapy
WO2004081046A3 (fr) Nouvelle composition
CA2744048A1 (fr) Vaccins unitemporels
WO2004030607A3 (fr) Therapie d'immunisation passive a base peptidique pour le traitement de l'atherosclerose
CN101595126A (zh) 第一屋尘螨2类过敏原用于治疗对第二屋尘螨2类过敏原的过敏症的用途

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase